Last Updated : August 7, 2025
Details
Generic Name:
olezarsen
Project Status:
Received
Therapeutic Area:
Familial chylomicronemia syndrome (FCS)
Manufacturer:
Theratechnologies Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0902-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
As an adjunct to diet in adult patients for the treatment of familial chylomicronemia syndrome (FCS).
Submission Type:
Initial
Submission Complexity:
Complex Review
Fee Schedule:
Pending
Indications:
As an adjunct to diet in adult patients for the treatment of familial chylomicronemia syndrome (FCS) .
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | June 18, 2025 |
|---|---|
| Call for patient/clinician input closed | August 11, 2025 |
| Submission received | July 29, 2025 |
| Submission accepted | - |
Last Updated : August 7, 2025